← All organizations
Highest phase reached
Phase 4
First clinical trial
Sep 1, 2012Last known activity
Oct 31, 2025
Timeline
1840s
- Dec 29, 1845
State of Texas— Founded
Drugs by trial phase (42 distinct, 23 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (3 own, 0 via acquisition)
Phase 2 (32 own, 0 via acquisition)
Phase 1 (6 own, 0 via acquisition)
Indications
Studied for
- Blast Crisis
- Breast Neoplasms
- Carcinoma, Renal Cell
- Graft vs Host Disease
- Hematologic Diseases
- Leukemia
- Leukemia, Erythroblastic, Acute
- Leukemia, Megakaryoblastic, Acute
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Accelerated Phase
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myelomonocytic, Juvenile
- Lung Neoplasms
- Lymphoma
- Lymphoma, Mantle-Cell
- Melanoma
- Multiple Myeloma
- Myelodysplastic Syndromes
- Papilloma
- Preleukemia
- Skin Neoplasms
- Syndrome
Recent trials (23)
- NCT06665100CollaboratorPhase 2Oct 31, 2025
- NCT06284564CollaboratorPhase 2Aug 7, 2024
- NCT06536413CollaboratorPhase 1/Phase 2Jul 29, 2024
- NCT06004336CollaboratorPhase 2Oct 31, 2023
- NCT05724563CollaboratorPhase 2Jun 1, 2023
- NCT05672927CollaboratorPhase 4Jan 18, 2023
- NCT05431595CollaboratorPhase 2/Phase 3Dec 30, 2022
- NCT04614194CollaboratorPhase 2Dec 22, 2020
- NCT04200534CollaboratorEarly Phase 1Jan 10, 2020
- NCT03943875CollaboratorPhase 4Jun 17, 2019
- NCT03747042CollaboratorEarly Phase 1Dec 19, 2018
- NCT03219047CollaboratorEarly Phase 1Sep 30, 2018
- NCT03093350CollaboratorPhase 2Aug 1, 2017
- NCT03097796CollaboratorPhase 1Apr 1, 2017
- NCT02494167CollaboratorPhase 1Feb 1, 2016
Details
- Founded
- Austin, TX, US Dec 29, 1845
- Last known activity
- Oct 31, 2025